COUR Pharma Secures FDA Orphan Drug Designation for CNP-106 in Generalized Myasthenia Gravis
CHICAGO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company developing first-in-class, antigen-specific immune tolerance therapies for...